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Purpose: The purpose of this study is to evaluate the feasibility, efficacy and toxicity of SBRT for treatment of
unresectable hepatic or lung metastases regardless of their primary tumor site for patients who received prior
systemic chemotherapy.
Methods and materials: Between July 2007 and June 2010, 90 patients were treated with the CyberKnifeW SBRT
system for hepatic or pulmonary metastatic lesions. Medical records were retrospectively reviewed. The endpoints
of this study were local control, overall survival (OS), disease-free survival (DFS), local relapse free-survival (LRFS), and
treatment toxicity.
Results: A total of 113 liver and 26 lung metastatic lesions in 52 men (58%) and 38 women (42%) were treated.
Median follow-up was 17 months. Median age at treatment was 65 years (range, 23–84 years). Primary cancers were
63 GI, three lung, eight breast, four melanoma, three neuro-endocrine tumors, and three sarcomas. Median
diameter of the lesions was 28 mm (range, 7–110 mm) for liver and 12.5 mm (range, 5–63.5 mm) for lung. Local
control rates at 1 and 2 years were 84.5% and 66.1%, respectively. Two-year overall survival rate was 70% (95% CI:
55–81%). The 1 and 2-year disease-free survival rates were 27% (95% CI: 18–37%) and 10% (95% CI: 4–20%),
respectively. Median duration of disease-free survival was 6.7 months (95% CI: 5.1–9.5 months). Observed toxicities
included grade 1–3 acute toxicities. One grade 3 and no grade 4 toxicity were reported.
Conclusion: High-dose SBRT for metastatic lesions is both feasible and effective with high local control rates.
Overall survival is comparable with other available techniques. Treatment is well tolerated with low toxicity rates. It
could represent an interesting treatment option for oligometastatic patients not amenable to surgery, even when
patients had been pre-treated with chemotherapy.
Summary: Stereotactic body radiotherapy (SBRT) has previously been successfully used in the treatment of
metastatic lesions. It could be considered as a curative option for oligometastatic patients. This retrospective study
involved 90 patients, designed to test potential effectiveness of SBRT in the treatment of oligometastases
irrespective of primary. Results suggest SBRT could be an effective treatment extending patients’ life span. This
treatment appears to be more effective when used prior to multiple systemic treatment regimens.
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Over the past decade, stereotactic body radiation therapy
(SBRT) has emerged as an alternative treatment option
for patients with liver [1,2] and lung [3,4] lesions. The
term "oligometastases" was first described by Hellman
and Weichselbaum [5] in 1995 as a less-advanced state
of metastatic disease amenable to and potentially curable
with local therapy. The term "oligometastases" is most
often used to describe five or fewer metastatic lesions
[6]. Often, this pathology has a slow rate of progression,
justifying focal treatments.
Main therapeutic options for oligometastases remain
surgery or radiofrequency. Due to its high level of preci-
sion which allows hypofractionnation, SBRT has gained
interest as a curative treatment option for inoperable
patients with lung cancer, liver tumors, or oligometas-
tases. The concept of local treatment for oligometastatic
lesions exists since only a few years [7-9] Researchers
have reported encouraging data for liver metastases trea-
ted with SBRT. Katz et al. [10] have reported a local con-
trol rate of 76% and 57% at 10 and 20 months,
respectively, with 69 patients. For lung metastases,
Rusthoven et al. have reported local control rates of
100% and 96% at 1 and 2 years, respectively [11]. SBRT
can be delivered without tumor tracking using a stereo-
tactic frame or the breath-hold technique, or most re-
cently, with a real-time tumor tracking system, which is
available with the CyberKnifeW System (Accuray Incor-
porated, Sunnyvale, CA). Most studies have reported
results from treatments delivered without tracking [12].
With real-time tracking, patients can breathe freely dur-
ing treatment sessions.
Milano reported a study of 121 patients with oligome-
tastases from any site analyzing survival and tumor con-
trol with encouraging results [6]. Bone metastases
appeared to be associated with a fourfold reduced hazard
of death. To our knowledge, no previous study has been
reported with this technique of SBRT for a pooled ana-
lysis of lung and liver metastases.
We report a retrospective study of 90 patients with
139 visceral oligometastases (lung or liver), regardless of




Patients treated between July 2007 and June 2010 were
included and medical records were retrospectively
reviewed. Patients with oligometastases (1 to 5 lesions)
from any primary site and not amenable to surgery, due
most of the time to anesthesia were eligible. Other inclu-
sion criteria were a Performance Status >3 (WHO scale),
number of hepatic or lung lesions <5, and lesion size
<100 mm for hepatic metastases and <70 mm for lunglesions. Clinical data on 90 patients presenting with 113
hepatic and 26 lung metastases were collected and ana-
lyzed. Patients and tumor characteristics are presented
in Table 1. Treatment response was assessed using the
RECIST 1.1 criteria. Toxicity was evaluated with the
CTCAE v4.0. Written informed consent was obtained
from the patient for publication of this report in accord-
ance with the guidelines of the French National Cancer
Institute (Institut National du Cancer) required when
assessing the efficacy and toxicity of a novel therapy,
Methods
SBRT was delivered with Cyberknife, an integrated
image-guided frameless stereotactic radiation therapy
system. It is comprised of a robotic arm coupled with a
compact 6-MV X-Ray linear accelerator and a real-time
imaging system. Different collimators with diameters
ranging from 5–60 mm are used with the linac. Two X-
Ray tubes are positioned in the treatment room at a 45°
angle. Images created are registered to the treatment-
planning console. This system detects a difference of
0.06 mm in translation and rotation. For liver metasta-
ses, all patients were treated with the SynchronyW Re-
spiratory Tracking System. Four gold fiducial markers
were inserted around the lesion 2 weeks before the treat-
ment planning. For lung metastases, patients could be
treated with either XsightW Lung Tracking System
(Accuray) or, using an internal target volume (ITV), with
XsightW Spine Tracking System (Accuray). These track-
ing methods did not require the implantation of fiducial
markers. For the planning computed tomography (CT)
study, patients were immobilized in an external vacuum-
type body mold. An abdominal belt could be used for
liver lesions in order to decrease respiration amplitudes.
A 4D CT-scan was performed for patients with liver
or lung metastases, respectively, with a 1-mm slice thick-
ness and reconstruction in 3-mm slices. For the lung
patients tracked with Xsight Spine, ITV was defined
using the data from the 4D CT-Scan performed for
treatment planning. For patients treated with tumor
tracking, GTV was contoured. GTV or ITV was
expanded by 5 mm to create the clinical tumor volume
(CTV). CTV was expanded by 3 mm to obtain the plan-
ning target volume (PTV). SBRT planning was per-
formed with Accuray’s MultiplanW treatment planning
software. Dose was prescribed to the 80% isodose line
and delivered to the target volume over a mean duration
of 8 days (range, 3–22 days). The median fractionnation
scheme was three fractions of 15 Gy (range, 9–20 Gy).
Critical organ dose constraints are detailed in Table 2.
Follow-up
All patients were seen every 3 months with a new CT-
Scan. Treatment response was evaluated every 3 months
Table 1 Patient characteristics
Patients Total (n = 90) %
Gender: Female 38 42%
Male 52 58%
Age at diagnostic, median (range): 62 years (22–82)
Age at SBRT, median (range): 65 years (23–84)







Adenocarcinoma Histology: Hepatic (n = 75) 61 81%
Lung (n = 15) 7 47%






Primary for squamous cell histology : 7
Esophagus 5 71%
Lung 2 29%
Other histologies : 15 17%
Lesions : Lung 15 17%
Hepatic 75 83%






At initial diagnostic 43 49%
Within one year 20 23%
More than 1 year 25 28%
Time from diagnosis of metastasis to
SBRT treatment, median (range)
25.6 months (1.2 – 93.6)
Previous local treatment :
Hepatic (n = 75) 53 71%
Lung (n = 15) 0 0%
Prior chemotherapy: 91%
Hepatic lesions (n = 75) 70 93%
Lung lesions (n = 15) 12 92%
Prior progressive disease with Chemo:
No 67 82%
Table 1 Patient characteristics (Continued)
Yes 15 18%
More than 3 chemotherapy
regimens before SBRT :
26,6%
Hepatic lesions (n = 75) 21 28%
Lung lesions (n = 15) 3 20%
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defined as complete disappearance of tumor or only fi-
brosis in the image, partial response (PR) defined as
tumor shrinkage of at least 30%, stable disease (SD)
defined as no radiologically measurable difference and
progressive disease (PD) defined as a tumor increase of
at least 20%. Local control was defined as CR, PR, or SD
during follow-up based on imaging. Acute toxicity was
evaluated using CTCAE v4.
Statistics
Descriptive statistics were used for categorical variables
(frequency and percentage) and continuous variables
(median and range). The following variables were ana-
lyzed: age, gender, primary site, histology, previous local
or systemic treatment, time from initial diagnosis to first
metastasis, time from the diagnosis of the first metasta-
sis to SBRT, total dose received, number of fractions,
dose per fraction, size of the target lesions, and treat-
ment time. All time to event endpoints were calculated
from the initiation of treatment. Overall survival
included death from any cause. Disease-free survival
counted events as a progression of an existing target le-
sion, appearance of new lesions within the same organTable 2 Critical organ constraints
Constraints
Liver metastases Normal liver V21 < 33%
V15 < 50%
stomach V21 < 5 cm3
Spinal cord maximal dose < 22 Gy
Kidney V 15 < 33%
Lung metastases normal lung (= volume of
right + left lung – PTV)
V5 < 50%
V10 < 30%
One lung V 20< 20%
Heart V24 < 15 cm3
Dmax< 30 Gy
trachea and principal bronchi V 15 < 4 cm3
V 20 < 1 cm3
Dmax< 30 Gy
esophagus V 21 < 5 cm3
Dmax< 25 Gy
Table 3 Characteristics and response of metastatic lesions
Lesions Total (n = 139) %
Number of lesions:
Hepatic metastases 113 81%
Lung metastases 26 19%
Lesion diameter, median (range):
Liver (n = 111) 28 mm (range 7–100)
Lung (n = 26) 12.5 mm (range 5–63.5)




Surgery of same lesion 2 2%
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whichever occurred first. Local failure included events
involving pre-existing treated lesions only. Survival rates
were estimated by the Kaplan-Meier method and groups
were compared with the logrank test. P values smaller
than 0.05 were considered statistically significant.
Results
Patient characteristics
Ninety patients were treated (52 male and 38 female).
Median age at diagnosis was 62 (range, 22–82) and me-
dian age at the time of SBRT was 65 (range 23–84).
Seventy-one percent of patients had only one metastatic
lesion. No patient had both liver and lung lesions.
Histologies of the metastatic lesions were: 68 adenocar-
cinomas including 57 colorectal tumors, eight breast
tumors, one stomach cancer, one lung, and one kidney
cancer case; seven squamous-cell carcinomas from
esophagus and lung; and 15 other histologies [four mela-
nomas, three neuro-endocrine tumors, three sarcomas,
one GIST (gastro-intestinal stromal tumor), one papil-
lary thyroid tumor, one pneumoblastoma, one adenoid
cystic cancer, two small-cell lung cancers]. Forty-nine
percent of the patients had metastases at the time of ini-
tial diagnosis. Median time from diagnosis of metastases
to start of CyberKnife treatment was 25.6 months
(range, 1.2–93.6 months). Eighty-five percent of patients
had received prior chemotherapy; 93% and 92% of liver
and lung patients, respectively. Twenty-seven percent of
patients treated with SBRT had received more than three
cycles of chemotherapy prior to CyberKnife, 28% and
21% of liver and lung patients, respectively. No patients
had received prior radiotherapy.( Table 1)
There were 113 hepatic and 26 lung metastatic lesions
(Table 3). Median lesion diameter was 28 mm (range, 7–
100) for liver and 12.5 mm (range, 5–63.5) for lung. CR
rate was 52%, PR 18%, SD 8%, and PD 22%. Except for
one patient, none of the patients with lung metastases
had any previous local treatment compared to the 53/75
(71%) patients with 68/113 (69%) hepatic metastases
who were previously treated locally with surgery to the
treated lesion (2%), surgery to other lesions (44%), chemo-
embolization (3%), or radio frequency ablation (12%).
Treatment characteristics
Fifty eight patients were treated with three fractions of
9 Gy (1.1%), 10 Gy (2,2%); 12 Gy (3.3%), 13 Gy (2.2%),
15 Gy (53.3%), or 20 Gy (2.2%) times (Table 4). The
20 Gy per fraction regimen was only administered for
lung metastases. Thirty patients (35.6%), were treated
with 4 fractions of 10 Gy. One patient was treated with
six fractions of 6 Gy for a total dose of 36 Gy to a lung
metastasis because of the central localization of the le-
sion and one patient was treated with 6 fractions of 9 Gyfor a liver metastasis for a total dose of 54 Gy due to the
duodenum proximity. All patients received a total dose
of 27–60 Gy (median dose, 45 Gy). Median treatment
time was 8 days (range, 3–22) ( Table 4). Treatment was
delivered in two weeks, with a session being performed
every 2 or 3 days.
Treatment efficacy
Median follow up was 17 months ( 95%CI 14-21). The
overall response rate was complete for 52% of the
lesions, partial for 20%, stable for 9%, and progressive
for 20% of the lesions. Results were similar for hepatic
and lung lesions. At last follow-up, 21 patients had died
and 17 patients were disease-free. The local control rate
Table 4 Cyberknife treatment characteristics (by patients)
Patients Hepatic (n = 75) Lung (n= 15) All Patients
(n = 90)
Dose per fractions, n (%)
6 0 1 1 (1,1%)
9 2 0 2 (2,2%°
10 31 (41%) 1 32 (35,6%)
12 3 0 3 (3,3%)
13 2 0 2 (2,2%)
15 37 (49%) 11 (73%) 48 (53,3%)
20 0 2 2 (2,2%)
Total dose, n (%)
27 1 0 1,1%
30 2 0 2,2%
36 3 1 4,4%
39 2 0 2,2%
40 29 (39%) 1 30 (33,3%)
45 37 (49%) 11 (73%) 48 (53,3%)
54 1 0 1,1%
60 0 2 2,2%
Treatment duration,
median (range)
8 days(3 – 22)
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(Figure 1A). The 1 and 2-year disease-free survival rates
were 27% (95% CI: 18–37%) and 10% (95% CI: 4–20%),
respectively (Figure 1B). Median duration of disease-free
survival was 6.7 months (95% CI: 5.1–9.5 months). The
2-year overall survival rate was 70% (95% CI: 55–81%)
(Figure 1C).
Toxicity
Side effects were generally mild. Observed toxicites ranged
from grade 1 to 2 in the CTCAE v.4. Toxicity for patients
treated for hepatic lesions consisted mainly of digestive
adverse events : we recorded 19 nausea (17%), 10 vomiting
(9%), three gastritis (2,5%), three anorexia (2,5%), 17 hep-
atic pain (15%) and 9 asthenia. (8%) Toxicity for patients
treated for lung lesions was lower, consisting mainly of as-
thenia (5= 19%) radiation pneumonitis (5= 19%) and
pleural effusion (3= 11,5%). We encountered two grade 3
toxicities : one gastritis in a patient with a hepatic lesion
and one epidermitis in a patient treated for two different
hepatic lesions.
Univariate analysis
Regarding local control, neither tumor size nor dose was
found to be statistically significant. Adenocarcinoma
appeared to present a higher risk of failure than other
histologies: HR=2.74 (95% CI: 0.95–7.88, p = 0.036).
Control local rate was 82% for adenocarcinoma comparedto 89% for other histologies at 1 year and 59% at 2 years
compared to 80% for other histologies. Regarding disease-
free survival, patients with lung lesions were at a lower
risk of failure than patients with hepatic lesions: HR=0.47
(95% CI: 0.23–0.95, p = 0.02). Patients with a history of re-
ceiving chemotherapy were at higher risk of failure com-
pared to those without: HR=4.51 (95% CI: 1.10–18.47,
p = 0.007) (Table 5). Other factors such as progressive dis-
ease following earlier chemotherapy, more than three pre-
vious chemotherapy regimens, and time between diagnosis
of the first metastasis and treatment by SBRT were not
found to be prognostic for disease-free survival. As far as
local control is concerned, female patients had a tendency
for lower risk of local failure: HR=0.48 (95% CI: 0.21–1.10,
p= 0.07). No factor had any impact on overall survival.
Discussion
The concept of oligometastasis
Oligometastasis is an emerging paradigm in oncology. It is
described as a distant extension of a primary cancer with
an isolated site or less than five sites of metastases [6].
Oligometastases could be seen as clinical manifestations
of a systemic disease requiring systemic treatment. But
they can also be considered as consequences of a slow,
controllable disease progression, curable with local treat-
ments. Local treatments include surgery, radiofrequency,
conformal or stereotactic body radiation therapy. The use
of SBRT has seen rapid growth as a noninvasive treatment
modality and provides a new treatment alternative for in-
operable or elderly patients. Salama and al. [13] recently
published a dose escalation trial in patients with 1 to 5
metastases in SBRT. Maximal dose was 48 Gy but the
maximal dose tolerated was not reached. 2 year overall
survival rate was 56.7% and progression free survival rate
were 33.3% and 22% at one and two years respectively.
Our progression-free survival rate were lower but we fo-
cused our study on patients with visceral metastasis, which
might explain this difference. Indeed in the study pub-
lished by Salama et al., 13.3% of patients had only bone
metastases, which could be a factor of better prognosis, as
Milano et al. have shown [6].
Treatment efficacy and predictive factors
Several studies have been published on different SBRT
methods. Most of them report about primary and sec-
ondary lesions without distinction [12,14]. Rusthoven
et al. have reported 47 patients with 63 hepatic lesions.
Among the patients, 69% had received at least one prior
systemic therapy regimen for metastatic disease (zero to
five regimens) and 45% had extrahepatic disease at study
entry. Actuarial in-field local control rates at one and
two years after SBRT were 95% and 92%, respectively.
These rates are better than those reported in our study.












139 112 71 37 19 9 4Target lesions
Number at risk








































90 51 20 6 5 3
790 76 60 34 21
Figure 1 Kaplan-Meier Survival curves. A. Local relapse-free survival. B. Disease-free survival. C. Overall survival.
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Table 5 Predictive factors for disease free survival
DFS
Patients HR : (95% CI) (p)
Gender: Female 1.17: (0.74 – 1.86) 0.51
Age at SBRT 65+ 0.72: (0.46 – 1.15) 0.17
Adenocarcinoma Histology: 1.28 : (0.75 – 2.19) 0.36
Lesions : pulmonary 0.47 : (0.23 – 0.95) 0.02
Number of lesions : 3+ 1.17 : (0.70 – 1.98) 0.55
Number of hepatic lesions : 3+ 1.40 : (0.79 – 2.48) 0.25
Timing of Metastases: < one year 0.67: (0.37 - 1.22) 0.19
More than 1 year 1.04: (0.60 – 1.79) 0.90
Prior chemotherapy 4.51: (1.10 – 18.47) 0.007
3+ chemotherapies before SBRT : 1.20: (0.63 – 2.25) 0.59
Prior PD with previous CT 1.31: (0.74 – 2.32) 0.37
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not received any chemotherapy before SBRT. There are
also few data on lung metastases. Studies report local
control rates from 72–100% at 1 year and from 78–96%
at 2 years [11,14-16].
Our study evaluated feasibility of SBRT on hepatic and
pulmonary oligometastatic lesions from a multitute of
primaries. Local control rates at 1 and 2 years were, re-
spectively, 84.5% and 66.1%. These results are similar to
other SBRT reports on liver metastases in which 1-year
local control rates ranged from 71–100% and 2-year
rates from 30–92% [1,17,18]. In our cohort, 49% of the
patients had metastases at initial diagnosis. This fact
may have affected our results because of the prognosis
of such disease that is often considered more aggressive.
Adenocarcinoma displayed worse prognosis than other
histologies: HR= 2.74 (95% CI: 0.95–7.88), p =0.036.
This could suggest that a more potent dosing regimen
should be employed when treating metastases with
adenocarcinoma pathology. Indeed, dose has not been
shown as a predictive factor and treatment was well tol-
erated. This is probably also related to the localisation of
the treated lesions. Majority of adenocarcinoma metasta-
ses were hepatic lesions as opposed to being lung
lesions. These results were based on a sub-group ana-
lysis and care needs to be taken in the interpretation.
Regarding disease-free-survival, patients with lung
lesions were at lower risk of failure than those with hep-
atic lesions (HR= 0.47, 95% CI: 0.23–0.95, p = 0.02). As
there is no previous study comparing lung and hepatic
metastases treated with SBRT, this result appears to be a
new finding to take into account when considering
SBRT as a treatment option. However, number of lung
lesions was lower than number of liver lesions Fur-
thermore, the total dose and fractionnation were differ-
ent between lung and hepatic tumors. 11/15 patients
with lung tumors received 15 Gy x 3 and 2/15 received20 Gy x 3 while only 37/75 patients with liver tumors
received 15 Gy x 3 and all the rest received lower doses.
Another explanation could be that the lesions' median
diameter for lung metastases was 12.5 mm versus
28 mm for hepatic lesion. Our univariate analysis did
not find a difference in local control based on the pri-
mary tumor site, suggesting that SBRT could be used to
treat oligometastases from any primary. Still, according
to other studies, the role of the primary tumor site in
the case of liver metastases remains unclear [18]. Lee
and al. didn't find a difference in overall survival be-
tween colorectal, breast and other primaries of metasta-
ses treated (respectively 63% (95% CI, 44% to 78%), 79%
(95% CI, 36% to 94%), and 38% (95% CI, 14% to 62%).
Dose, within dose range used in this study, did not ap-
pear to be a factor in disease-free or overall survival. Al-
though, this result has been confirmed in other studies.
McCammon et al. and al [12] found that increased dose
and smaller gross tumor volume were significant predic-
tors of higher local control rates. Their patients treated
with 54 Gy or more had a 3-year actuarial local control
rate of 89.3% compared with 59.0% and 8.1% for those
treated with 36–53.9 Gy and less than 36 Gy. The opti-
mal treatment dose has not been defined yet and should
be the subject of future studies.
Toxicity
In our study, treatment was well tolerated. There were
no grade 4 events and only one case of grade 3 gastritis
and epidermitis. All of the other events were grades 1 or
2. The most common acute toxicities were nausea and
pain at the time of treatment. None of the toxicities pre-
vented any patient from completing the treatment and
were transitory. Rusthoven et al. have reported similar
results with also one grade 3 event and no grade 4
events [17]. Lee et al. have reported two cases of grade 3
liver enzymes-related toxicities and six acute grade 3
toxicities in the form of two case of gastritis, two cases
nausea, one lethargia, and one thrombocytopenia [18].
They also had one grade 4 toxicity in the form of
thrombocytopenia. A longer follow-up period is neces-
sary to detect potential long-term toxicities.
SBRT and previous chemotherapy regimens
We wondered whether or not pre-treated patients with
metastatic disease could benefit from SBRT. Most of our
patients had received prior chemotherapy (91%), with a
high number of chemotherapy regimens, 27% of them
receiving more than three regimens, which may have
increased the radioresistance of the metastases. We
found that a patient’s history of prior chemotherapy was
a major risk factor in recurrence outside the treatment
volume (HR= 4.51, 95% CI: 1.10–18.47, p = 0.007). Also,
the number of previous chemotherapy regimens
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apy significantly correlates with a higher risk of failure.
One hypothesis that could explain this finding could be
that the previous chemotherapy regimens, received by
the patients, selected tumoral clones with a lower sensi-
tivity to radiation, even if no study has been published
to prove it. This suggests that SBRT should perhaps be
used as a local treatment for metastases before the ad-
ministration of several systemic therapies.
Conclusion
Ablative SBRT for liver and lung metastases achieves
high 1- and 2-year local control rates, while minimal
and invasive. Toxicitiy was very low consisting mainly of
grade 1 and 2 nausea. The results indicate that ablative
SBRT is a promising option even for pre-treated patients
with oligometastases.. Comparative studies are needed to
better assess this issue.
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